Healthcare / BiotechnologyCanadian Sec
$0.60
+0.02 (+3.45%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-6.0M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$45M
P/E
N/A
•EV/EBITDA
N/A
•ROE
368.1%
↑Gross Margin
N/A
•Debt/Equity
-0.49
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.34x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-13.2M · FCF $-4.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-13.2M | $-13.2M | $-6.8M | $-7.3M | $-2.9M |
| EBITDA | $-12.7M | $-12.7M | $-6.6M | $-7.3M | $-2.9M |
| EPS | -0.30 | -0.30 | -0.17 | -0.20 | -0.11 |
| Balance Sheet | |||||
| Debt/Equity | -0.49 | -0.49 | 1.11 | — | — |
| Current Ratio | 3.37 | 3.37 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-4.5M | $-4.5M | $-7.7M | $-6.0M | $-2.3M |
| Returns | |||||
| ROE | 368.1% | 368.1% | -431.8% | 1894.9% | -52.1% |
| Valuation | |||||
| P/B | — | — | 73.18 | — | 34.08 |
| Growth & Yield | |||||
| EPS Growth | -76.5% | -76.5% | 15.0% | -81.8% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-20.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.17 → -0.30
Residual
-20.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.